drugset / Trial / NCT04526210
Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants
RandomizedCrossoverOpen-labelTreatment
Summary
This is a Phase 1, randomized, 2-period, 2-sequence, cross-over study designed to determine the effect of ALXN1840 on the metabolism of bupropion, a sensitive cytochrome P450 2B6 (CYP2B6) substrate, in healthy male and female participants. The safety and tolerability of ALXN1840 will be determined along with ALXN1840 pharmacokinetics (PK) in plasma as measured via total molybdenum with the coadministration of bupropion.
Timeline
- Start
- 2020-10-21
- Primary completion
- 2021-05-28
- Completion
- 2021-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupropion | Small molecule | 150 mg | Oral |
| Subject | TIOMOLIBDATE CHOLINE | Small molecule | 60 mg | Oral |